Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
AstraZeneca
University Hospitals Bristol and Weston NHS Foundation Trust
Janssen Research & Development, LLC
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Brigham and Women's Hospital
Pfizer
Institute of Cancer Research, United Kingdom
Astellas Pharma Inc
Institut Cancerologie de l'Ouest
Medtronic - MITG
NRG Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jonsson Comprehensive Cancer Center
University of Washington
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
Day One Biopharmaceuticals, Inc.
University of Washington
Bristol-Myers Squibb
G1 Therapeutics, Inc.
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Trishula Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Trishula Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
NGM Biopharmaceuticals, Inc
SWOG Cancer Research Network
Aprea Therapeutics
University of Chicago
Bayer
Elevation Oncology
University of Kansas Medical Center
Hoosier Cancer Research Network
Hoffmann-La Roche
Columbia University
Emory University
UNC Lineberger Comprehensive Cancer Center
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Stanford University
SWOG Cancer Research Network
SWOG Cancer Research Network
University of Utah
UroGen Pharma Ltd.
Istari Oncology, Inc.